Results 221 to 230 of about 254,581 (301)

Expression and Immunogenic Application of Recombinant DENV-2 rprM Protein for the Non-Invasive Detection of Salivary IgA Antibodies. [PDF]

Int J Mol Sci
García-Cordero J, Sánchez-Vargas LA, Luria-Pérez R, Vivanco-Cid H, Cedillo-Barrón L, García-Machorro J, Mellado-Sánchez G.   +6 more
europepmc   +1 more source

Increased anergic B cells and decreased antibody‐secreting cells during romiplostim treatment in patients with immune thrombocytopenia

British Journal of Haematology, EarlyView.
Summary Patients with immune thrombocytopenia (ITP) exhibit substantial heterogeneity in treatment responses. Approximately 30%–50% of patients maintain remission after discontinuation of thrombopoietin receptor agonists (TPO‐RA), suggesting immunomodulatory effects beyond enhanced thrombopoiesis.
Vivianne S. Nelson, Rebeca Gutiérrez‐Cózar, Rebecca Cornelis, S. Marieke van Ham, Anja ten Brinke, Rick Kapur   +5 more
wiley   +1 more source

Successful hemodialysis withdrawal with glucocorticoid treatment after achieving infection control in a case of crescentic IgA-dominant staphylococcus-associated glomerulonephritis. [PDF]

CEN Case Rep
Nishiyama Y, Matsumura M, Yasui Y, Omizo N, Saito T, Kawashima M, Seto N, Nagase Y, Morioka S, Katagiri D, Takano H.   +10 more
europepmc   +1 more source

Fulminant Multisystem IgA Vasculitis With Diffuse Alveolar Hemorrhage, Severe Gastrointestinal Hemorrhage, Paralytic Ileus, and Renal Involvement in an Adolescent: A Case Report. [PDF]

Clin Case Rep
Shan X, Zhu Y.
europepmc   +1 more source

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

British Journal of Haematology, EarlyView.
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz, Rémi Letestu, Mary Sartor, Stephen Mulligan, Marie C. Béné, Gavin Cull, Dennis Carney, William Renwick, Andrew Grigg, Cecily Forsyth, Gregory Hapgood, Emma Verner, Rosemary Harrup, Pauline Warburton, Kylie Mason, Richard Eek, Wojciech Janowski, Jean Pierre Vilque, Maya Latimer, Laurent Voillat, Sophie De Guibert, Bernard Drenou, Robert Blum, Caroline Dartigeas, Lachlan Hayes, Nicolas Daguindau, Mourad Tiab, Véronique Leblond, Andrew Shearer, Masa Lasica, Pierre Morel, Bohrane Slama, Anne Banos, Annie Brion, Emmanuelle Ferrant, Jessica Michel, Cécile Tomowiak, Edward Morris, Hanlon Sia, Kelly Kratzing, Belinda E. Butcher, Abdelmalek Dahmani, Stephen Robert Larsen, Piers Blombery, Florence Cymbalista, David J. Gottlieb   +45 more
wiley   +1 more source

Mucosal IgA to pre-fusion F protein predicts protection from RSV infection in a high burden setting. [PDF]

Nat Commun
Hodgson D, Jarju S, Gatcombe L, Francis S, Coleman T, Dowgier G, Wenlock RD, Lindsey BB, Danso M, Barratt N, Gomes M, Grouneva I, Jagne YJ, Kampmann B, Wu MY, Otter A, Flasche S, Kucharski A, de Silva TI.   +18 more
europepmc   +1 more source

Identifying regulatory muscle processes in infantile and adult Pompe patients using a multi‐omic and morphological approach

Brain Pathology, EarlyView.
The study highlights differences in the regulatory processes of skeletal muscle, such as sarcomeric contractility, lysosomal and autophagic function, metabolic activity and immune regulation, at transcriptomic and proteomic levels in infantile and adult Pompe disease.
Alexander Schaiter, Keerthika Lohanadan, Alexander Mensch, Andreas Hentschel, Angela Rosenbohm, Cornelia Kornblum, Angela Roth, Tara Procida‐Kowalski, Heidrun H. Krämer, Andreas Hahn, Jörg Höhfeld, Dieter O. Fürst, Werner Stenzel, Peter F. M. van der Ven, Andreas Roos, Marek Bartkuhn, Anne Schänzer   +16 more
wiley   +1 more source

Correction to: IgA autoantibodies demonstrate a novel mechanism of MuSK myasthenia gravis pathology. [PDF]

Brain
europepmc   +1 more source